MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. The company's testing solutions include Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patie…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-02 |
|---|---|---|---|---|
| Real | — | — | $-0.17 | $-0.17 |
| Estimado | $-0.11 | $-0.13 | $-0.15 | $-0.13 |
| Sorpresa | — | — | -13.3% | -30.8% |
| Métrica | MDXH | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 64.5% | 57.4% | +7.2% |
| Operating Margin | -13.4% | -34.4% | +21.0% |
| Net Margin | -31.1% | -32.5% | +1.4% |
| FCF Margin | -3.1% | -12.6% | +9.5% |
| ROE | — | -39.2% | — |
| ROA | -22.7% | -30.9% | +8.3% |
| Current Ratio | 1.08 | 2.73 | -1.65 |
| Debt / Equity | -6.30 | 0.28 | -6.58 |
| Tendencia (Piotroski) | FY25 | FY24 |
|---|---|---|
| ✗Rentabilidad sobre activos positiva | -22.7% | — |
| ✗Flujo de caja operativo positivo | −$2M | −$19M |
| ✓Rentabilidad sobre activos al alza | -22.7% | -24.2% |
| ✓Caja operativa/activos supera al ROA | -1.5% | ROA -22.7% |
| ✗Menos deuda a largo plazo | 51.5% | 32.4% |
| ✗Mejor liquidez (ratio corriente) | 1.08 | 1.57 |
| ✗Sin aumentar el nº de acciones | 50M | 33M |
| ✓Margen bruto al alza | 64.5% | 61.2% |
| ✓Rotación de activos al alza | 0.73 | 0.57 |
| Calidad del negocio | FY25 |
|---|---|
| ✗Margen FCF > 10 % | -3.1% |
| ✗ROCE > 10 % | -14.6% |
| ✓Ventas > 5 %/año (3 años) | 42.8% |
| ✓Deuda neta/EBITDA < 3x | -6.4x |
| ✓Reinversión (I+D + capex) > 3 % de ventas | 10.7% |
MDxHealth SA cotiza a 0.17 USD y tiene una capitalización bursátil de $17M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud